As of 4:02pm ET
| -0.35 / -0.66%|
The 32 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 52.18, with a high estimate of 62.90 and a low estimate of 31.68. The median estimate represents a -0.62% decrease from the last price of 52.51.
The current consensus among 34 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since December, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.